ABT vs CL: How Abbott Laboratories and Colgate-Palmolive Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ABT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABT and CL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABT and CL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Abbott Laboratories is a global healthcare company headquartered in North Chicago, Illinois, that discovers, develops, manufactures, and sells health care products in more than 160 countries through four segments: Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products. Medical Devices, the largest segment at roughly $21.4 billion in 2025 revenue, includes the FreeStyle Libre family of continuous glucose monitors, structural heart products (Navitor, TriClip), electrophysiology systems (AVEIR leadless pacemaker), vascular devices, and heart-failure technologies. Diagnostics contributes roughly $8.9 billion, Nutrition roughly $8.5 billion (anchored by Similac infant formula and Ensure adult nutrition), and Established Pharmaceuticals roughly $5.5 billion in branded generics sold primarily in emerging markets.

Full ABT guide

Colgate-Palmolive is a global consumer-staples company that makes everyday household and personal-care products. It is a worldwide leader in oral care, where its Colgate-branded toothpaste, toothbrushes, and mouthwash hold a leading global share, and it also sells personal care (soaps, body wash, deodorants under brands like Palmolive, Softsoap, Irish Spring, and Sanex), home care (dish and surface cleaners such as Palmolive and Ajax), and pet nutrition through its Hill's Pet Nutrition business (Science Diet and Prescription Diet). Colgate makes money by selling these branded, frequently repurchased products at scale across more than 200 countries and territories, with a particularly large presence in emerging markets. Its competitive advantages come from powerful brands, vast distribution, and pricing power on staple goods. Headquartered in New York City, Colgate is a defensive, dividend-paying company whose products people buy regardless of the economic cycle.

Full CL guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ABT drivers: FreeStyle Libre: A Platform, Not Just a Product; Cardiovascular and Electrophysiology Momentum.
• CL drivers: Oral-care leadership and emerging markets; Hill's Pet Nutrition growth.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The most acute near-term risk is infant formula litigation: juries have delivered verdicts including a $53 million compensatory award in late March 2026 and a separately upheld $495 million verdict, with hundreds of additional NEC-related cases still pending, and a securities class action filed in 2026 adds a parallel legal exposure track targeting alleged investor misstatements. For CL, colgate's growth is structurally slow: it competes in mature, saturated staples categories where volume gains are hard to come by and much of recent revenue growth has come from price increases that may not persist.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABT if you believe its drivers more; CL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABT and CL guides.

ABT. ABT's trailing GAAP P/E of roughly 26x sits below its own 3-year, 5-year, and 10-year historical averages, and is modestly above the Medical Devices and Instruments industry median of roughly 25x, suggesting the market has re-rated the stock from COVID-era growth-premium levels while still assigning a quality multiple. Revenue growth has remained consistently positive in the 5-7% range even as GAAP EPS was pressured in FY2025 by a year-over-year comparison that included elevated one-time items. The FY2026 adjusted EPS guidance of $5.38-$5.58 implies a forward adjusted P/E in the high-teens to low-twenties range at recent share prices, which analysts broadly describe as modestly discounted relative to fundamental fair value estimates.

CL. Colgate trades at a premium consumer-staples multiple that reflects its defensive, recession-resistant cash flows, leading oral-care brands, the growth of Hill's, and a multi-decade dividend-raising record. The valuation premium is the market paying for stability and pricing power, balanced against the reality of slow underlying volume growth in mature categories.

Headline figures (approximate, 2026-06-27 (TTM through Q1 2026; share price data as of June 26, 2026)): ABT shows revenue (ttm) ~$45.1 billion, revenue (fy 2025) ~$44.3 billion (+5.7% YoY), net income (fy 2025) ~$6.5 billion, net profit margin (fy 2025) ~14.7%; CL shows revenue (ttm) ~$20 billion, operating margin ~20-21%, net income (ttm) ~$2.7 billion, dividend yield ~2-2.5% (Dividend King).

ABT and CL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABT and CL exposure against your real portfolio. It is not an investment adviser.